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Is There a Role for a Traditional Herbal   
Formula in the Treatment of Hepatitis C?  
Jenny Lam 
H epatitis C virus infection is prevalent in the United States, with an estimated 3.9 million people living with the disease.1 In 85% of cas-
es, acute hepatitis C proceeds to chronic infection, 20-
25% progress to cirrhosis, and of these 5% may devel-
op hepatocellular carcinoma (HCC) annually.2 It is the 
most frequent indication for liver transplantation, 
however this does not preclude disease recurrence.3 
The pathogenesis of hepatitis is related to the immune
-mediated hepatocyte injury secondary to cytotoxic T-
cell activation and cytokine release. Inflammation ac-
tivates parenchymal stellate cells, initiating a fibro-
genic cascade. The chronic cycle of oxidative damage, 
inflammation, necrosis, fibrosis and regeneration 
raises the potential for malignant transformation.4 
While cirrhosis is significantly associated with hepato-
cellular carcinoma, it has been shown that non-
cirrhotic livers with histologic evidence of advanced 
fibrosis have also developed HCC.5 Levels of fibrosis 
and inflammation are prognostic factors for end stage 
liver disease. Thus, if the host immune and fibrogenic 
response were contained, the progression of hepatitis 
C infection to HCC could be slowed or halted. 
Current treatment options include interferon/
ribavirin dual therapy, which has a 55% overall re-
sponse rate, and the newer triple drug therapy regi-
men with novel antivirals telapravir and bocepravir 
which has produced viral response in 30% of previous 
nonresponders to interferon /ribavirin dual therapy.2 
These newer drugs have improved outcomes for hepa-
titis C patients dramatically but there is still a signifi-
cant number who are either intolerant to the side-
effects of interferon which include bone marrow sup-
pression, depression, and rash,6 or do not respond to 
triple therapy, especially those with hepatitis C geno-
type 1. 7 Alternative therapies may have a place in 
treating these patients whose treatment is contraindi-
cated or ineffective. 
Sho-saiko-to (SST), also known as Xiao-chai-hu-tang (TJ
-9), is a traditional herbal formula that has been wide-
ly used in China and Japan for many centuries in 
treating chronic liver disease. SST comprises a mix-
ture of seven herbs in a 7.5 g daily formulation: Bu-
pleurum falcatum, Pinellia ternate, Scutellaria bai-
calensis, Zizyphus jujuba, Panax ginseng, Glycyrrhiza, 
and Zingiber officinale.8 Many in-vitro and animal 
studies published in Japan have shown anti-oxidative, 
anti-proliferative and anti-inflammatory effects.9 
However, randomized controlled trials in humans are 
few in number. 
In-vitro, SST was shown to induce apoptosis in HCC 
and cholangiocarcinoma cell lines, inhibit cell prolif-
eration and DNA synthesis, and induce cell cycle ar-
rest in phase G0 and G1.10 In rat studies, SST de-
creased lipid peroxidation with subsequent decreases 
in inflammatory response, hepatic stellate cell activa-
tion and procollagen formation.11,12 This is theoretical-
ly supposed to decrease fibrosis and cirrhosis, as well 
as the cycle of hepatocyte injury and regeneration, 
leading to a decrease in preneoplastic lesions. Rats 
with experimental hepatic fibrosis secondary to DMN 
and PS treated with 1.5% TJ-9 showed a reduction in 
fibrosis, α-SMA (marker of stellate cell activation), de-
creased BrDU incorporation (DNA replication), inhibi-
tion of oxidative burst and lipid peroxidation. The fla-
vonoids balcalein and baicalin were isolated and iden-
tified as active compounds, shown to suppress super-
oxide anion production.13 SST-fed rats experienced 
reduced reactive oxygen-mediated DNA mutations 
and decreased rates of hepatocarcinogenesis com-
pared to controls.14 Several rat models of hepatitis in-
duced by other hepatotoxins such as CCl4 and D-
galactosamine have shown decreased levels of trans-
aminases, fatty degeneration and necrosis.9 
A multicenter randomized controlled trial in humans 
by Hirayama et al. in 1989 followed 220 patients with 
chronic active hepatitis by liver biopsy randomized to 
either SST for 12 weeks or placebo with cross-over to 
SST.15 Hirayama and colleagues found that mean AST 
and ALT levels were significantly (P<0.05) decreased 
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in the treatment group compared to placebo group by 
12 weeks. After cross-over, the difference was nulli-
fied by the end of week 24. No difference in HBeAg 
decrease or anti-HBe increase was found at any time 
between the two groups. This study would have bene-
fited from a longer intervention period, since there 
was fluctuation in values in both groups over the 
short term. In addition, the specific statistical tests 
used were not clearly defined.  
In a 1995 landmark prospective randomized trial by 
Oka et al., 260 patients with cirrhosis were given the 
SST herbal formula in addition to conventional drug 
therapy and compared to control group with conven-
tional drug therapy alone. A significant (P=0.02) dif-
ference was found in the incidence of hepatocellular 
carcinoma and survival over 5 years (P=0.04) in pa-
tients without HBsAg, most of whom were HCV posi-
tive.16 When HBsAg status was not taken into account, 
there was no difference in overall incidence between 
trial and control groups. Conventional therapy was 
not defined in the study and the control group was 
not given placebo. Therefore, this may not discount 
the effect of believing that one is receiving effective 
treatment.17,18 
In the United States, a single arm phase II trial of 24 
patients with hepatitis C who were not candidates for 
interferon therapy received 2.5 g SST 3 times daily for 
12 months, and 67% experienced decreased AST, 75% 
experienced decreased ALT, and 38% had improved 
Knodell histological score.19 Viral load response was 
mixed, with 7 patients showing reductions, 10 increas-
es and 7 indeterminate. 5 patients had a two-point 
improvement in histological score on biopsy, which 
was deemed to be an adequate response rate to war-
rant larger phase III trials. This study was limited by 
small sample size, lack of control group, and high 
drop out rate (24 subjects completed of 41 enrolled). 
The high drop out rate may result in confounding if 
the patients who dropped out and the patients who 
completed the study differ in key respects.  
SST should be treated as a drug with potential interac-
tions and side effects. It has shown to decrease xan-
thine oxidase and CYP1A2 activity and therefore may 
result in unknown herb-drug interactions.20 It is not 
without adverse effects, as case reports have noted 
increased rates of interstitial pneumonitis and a risk 
of hepatic injury due to the herb formula itself.21 SST 
can be used in addition to but should not be a substi-
tute for conventional therapy or delay treatment initi-
ation. It is an option for patients who do not qualify 
for standard treatments. Thus far, clinical studies of 
SST have suffered from limitations and weak statisti-
cal interpretation. Additional adequately powered, 
randomized controlled studies are needed to study 
the effects of sho-saiko-to on chronic liver disease. 
Herbals and botanicals historically have brought 
about numerous major drugs used to treat disease, ie. 
digoxin (digitalis), statins (red yeast), and atropine 
(belladonna) to name a few. Old  Eastern medicinal 
remedies which have undergone centuries of herbal 
practitioners’ observations are an underutilized 
source for clinical study under current scientific 
standards. It is often difficult to evaluate the effects of 
herbals since they are composed of several com-
pounds in varying doses.   
The sale of over-the-counter herbals and supplements 
is largely an unregulated market, and consumers to-
day are increasingly taking these products for their 
purported disease-fighting properties. It is imperative 
for physicians to be aware of this trend, as herbals 
can have interactions with prescribed medications 
and delay appropriate care. 
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